Education
About Us
Working with TipRanks
Follow Us
OnKure Therapeutics (OKUR)
NASDAQ:OKUR
OKUR Stock Chart & Stats
$2.85
-$0.05(-0.63%)
At close: 4:00 PM EST
$2.85
-$0.05(-0.63%)
Day’s Range― - ―
52-Week Range$1.70 - $6.48
Previous CloseN/A
Volume8.61K
Average Volume (3M)86.56K
Market Cap
$38.61M
Enterprise Value-$31.30M
Total Cash (Recent Filing)$70.33M
Total Debt (Recent Filing)$687.00K
Price to Earnings (P/E)―
Beta1.34
Next Earnings
Mar 16, 2026EPS Estimate
-1.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.09
Shares Outstanding12,861,672
10 Day Avg. Volume131,167
30 Day Avg. Volume86,556
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)1.10
Price to Sales (P/S)0.00
P/FCF Ratio-2.24
Enterprise Value/Market Cap-0.81
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit74.71
Enterprise Value/Ebitda0.40
Forecast
1Y Price Target
$25.50Price Target Upside794.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Development MilestonesInitiation and dosing of two triplet therapy arms together with a planned presentation of Phase 1 PIKture-01 data in Q1 2026 create a clear clinical milestone that could clarify competitive positioning.
Pipeline Diversification And Market ExpansionExpansion into PI3KCA-driven vascular malformations diversifies the development program and opens a potential market for selective oral therapies addressing an unmet need.
Safety And PharmacokineticsOKI-219 showed a benign safety profile across dose levels and achieved steady-state exposure above preclinical activity thresholds, supporting its suitability for combination regimens.
Bears Say
Clinical Efficacy UncertaintyNo objective responses observed at the 900 mg dose level raise questions about clinical activity and whether higher or different dosing will be needed for meaningful benefit.
Competitive Positioning And Dosing ConvenienceIntravenous once-weekly dosing represents a disadvantage versus more patient-friendly oral PI3Kα inhibitors and could limit adoption if efficacy is similar.
Financial Runway And Funding RiskAvailable cash is modest relative to projected cash burn, increasing funding pressure and making upcoming clinical readouts critical for securing additional financing.
OnKure Therapeutics News
OKUR FAQ
What was OnKure Therapeutics’s price range in the past 12 months?
OnKure Therapeutics lowest stock price was $1.70 and its highest was $6.48 in the past 12 months.
What is OnKure Therapeutics’s market cap?
OnKure Therapeutics’s market cap is $38.61M.
When is OnKure Therapeutics’s upcoming earnings report date?
OnKure Therapeutics’s upcoming earnings report date is Mar 16, 2026 which is in 45 days.
How were OnKure Therapeutics’s earnings last quarter?
OnKure Therapeutics released its earnings results on Nov 06, 2025. The company reported -$1.09 earnings per share for the quarter, beating the consensus estimate of -$1.198 by $0.108.
Is OnKure Therapeutics overvalued?
According to Wall Street analysts OnKure Therapeutics’s price is currently Undervalued.
Does OnKure Therapeutics pay dividends?
OnKure Therapeutics does not currently pay dividends.
What is OnKure Therapeutics’s EPS estimate?
OnKure Therapeutics’s EPS estimate is -1.15.
How many shares outstanding does OnKure Therapeutics have?
OnKure Therapeutics has 12,861,672 shares outstanding.
What happened to OnKure Therapeutics’s price movement after its last earnings report?
OnKure Therapeutics reported an EPS of -$1.09 in its last earnings report, beating expectations of -$1.198. Following the earnings report the stock price went down -6.962%.
Which hedge fund is a major shareholder of OnKure Therapeutics?
Currently, no hedge funds are holding shares in OKUR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
OnKure Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$25.50 (794.74% Upside)
$25.50 (794.74% Upside)
Hedge Fund Trend
Decreased
By 13.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 3.0%
Last 30 Days ▲ 3.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-84.51%
12-Months-Change
Fundamentals
Return on Equity
-115.64%
Trailing 12-Months
Asset Growth
9.34%
Trailing 12-Months
Company Description
OnKure Therapeutics
OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.
OKUR Stock 12 Month Forecast
Average Price Target
$25.50
▲(794.74% Upside)